Literature DB >> 16925579

Staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison with conventional imaging.

Ukihide Tateishi1, Umio Yamaguchi, Testuo Maeda, Kunihiko Seki, Takashi Terauchi, Akira Kawai, Yasuaki Arai, Noriyuki Moriyama, Tadao Kakizoe.   

Abstract

The present study was conducted to compare the diagnostic accuracy between carbon-11 choline (11C-choline) positron emission tomography (PET)/computed tomography (CT) and conventional imaging for the staging of bone and soft tissue sarcomas. Sixteen patients who underwent 11C-choline PET/CT prior to treatment were evaluated retrospectively for staging accuracy. Conventional imaging methods consisted of 99,mTc-hydroxymethylene diphosphonate bone scintigraphy, chest CT and magnetic resonance imaging of the primary site. The images were reviewed and a consensus was reached by two board-certified radiologists who were unaware of any clinical or radiological information using hard-copy films and multimodality computer platform. Tumor stage was confirmed by histological examination and/or by an obvious progression in number and/or size of the lesions on follow-up examinations. Reviewers examining both 11C-choline PET/CT and conventional imaging classified T stage in all patients. Interpretation based on 11C-choline PET/CT, the Node (N) stage was correctly diagnosed in all patients, whereas the accuracy of conventional imaging in N stage was 63%. Tumor Node Metastasis (TNM) stage was assessed correctly with 11C-choline PET/CT in 15 of 16 patients (94%) and with conventional imaging in eight of 16 patients (50%). The overall TNM staging and N staging accuracy of 11C-choline PET/CT were significantly higher than that of conventional imaging (P < 0.05). 11C-choline PET/CT is more accurate than conventional imaging regarding clinical staging of patients with bone and soft tissue sarcomas. A whole body 11C-choline PET/CT might be acceptable for imaging studies of tumor staging prior to treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16925579     DOI: 10.1111/j.1349-7006.2006.00288.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

1.  Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas.

Authors:  Cristina Nanni; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

Review 2.  Nodal metastases of soft tissue sarcomas: risk factors, imaging findings, and implications.

Authors:  Jeffrey Rosenthal; Kenneth Cardona; Samia K Sayyid; Adam J Perricone; Nickolas Reimer; David Monson; Adam Daniel Singer
Journal:  Skeletal Radiol       Date:  2019-08-23       Impact factor: 2.199

3.  Hybrid PET/MR imaging in two sarcoma patients - clinical benefits and implications for future trials.

Authors:  Sasan Partovi; Andres A Kohan; Lisa Zipp; Peter Faulhaber; Christos Kosmas; Pablo R Ros; Mark R Robbin
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 4.  Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.

Authors:  Muhammad Kashif Rahim; Sung Eun Kim; Hyeongryul So; Hyung Jun Kim; Gi Jeong Cheon; Eun Seong Lee; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-01-22

5.  The effects of muscle exercise and bed rest on [18F]methylcholine PET/CT.

Authors:  Mark Roef; Wouter V Vogel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10-22       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.